Name | Number of supported studies | Average coverage | |
---|---|---|---|
plasmacytoid dendritic cell | 15 studies | 38% ± 13% | |
oligodendrocyte precursor cell | 9 studies | 31% ± 12% | |
pericyte | 9 studies | 19% ± 3% | |
basal cell | 9 studies | 29% ± 6% | |
adipocyte | 8 studies | 31% ± 6% | |
ciliated cell | 7 studies | 22% ± 6% | |
macrophage | 7 studies | 26% ± 5% | |
secretory cell | 6 studies | 37% ± 16% | |
epithelial cell | 6 studies | 39% ± 13% | |
goblet cell | 5 studies | 27% ± 12% | |
GABAergic neuron | 4 studies | 37% ± 8% | |
endothelial cell | 4 studies | 25% ± 8% | |
abnormal cell | 4 studies | 20% ± 2% | |
glutamatergic neuron | 4 studies | 45% ± 15% | |
oligodendrocyte | 4 studies | 24% ± 4% | |
pancreatic A cell | 3 studies | 43% ± 20% | |
club cell | 3 studies | 25% ± 5% | |
myeloid cell | 3 studies | 19% ± 5% | |
neuron | 3 studies | 27% ± 7% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 3921.78 | 1445 / 1445 | 99% | 216.04 | 181 / 183 |
stomach | 100% | 4993.52 | 359 / 359 | 98% | 146.46 | 281 / 286 |
intestine | 100% | 3015.22 | 965 / 966 | 98% | 137.29 | 518 / 527 |
brain | 99% | 3400.80 | 2622 / 2642 | 99% | 173.00 | 696 / 705 |
lung | 100% | 2991.07 | 577 / 578 | 98% | 182.14 | 1132 / 1155 |
bladder | 100% | 6717.76 | 21 / 21 | 97% | 311.05 | 490 / 504 |
kidney | 100% | 3480.89 | 89 / 89 | 92% | 121.44 | 830 / 901 |
pancreas | 94% | 1402.64 | 308 / 328 | 98% | 230.68 | 174 / 178 |
uterus | 98% | 1996.13 | 167 / 170 | 92% | 152.01 | 424 / 459 |
prostate | 96% | 2444.44 | 234 / 245 | 86% | 62.12 | 430 / 502 |
ovary | 87% | 920.89 | 156 / 180 | 88% | 72.46 | 379 / 430 |
breast | 99% | 2423.18 | 453 / 459 | 65% | 46.89 | 728 / 1118 |
skin | 71% | 682.07 | 1280 / 1809 | 77% | 92.33 | 362 / 472 |
thymus | 80% | 707.04 | 524 / 653 | 62% | 39.73 | 375 / 605 |
ureter | 0% | 0 | 0 / 0 | 100% | 312.98 | 1 / 1 |
adipose | 100% | 3114.27 | 1201 / 1204 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 96% | 168.61 | 43 / 45 |
spleen | 95% | 1515.74 | 228 / 241 | 0% | 0 | 0 / 0 |
adrenal gland | 45% | 302.10 | 117 / 258 | 38% | 24.67 | 88 / 230 |
heart | 80% | 778.20 | 692 / 861 | 0% | 0 | 0 / 0 |
liver | 31% | 269.80 | 71 / 226 | 34% | 34.89 | 140 / 406 |
muscle | 51% | 392.23 | 409 / 803 | 0% | 0 | 0 / 0 |
blood vessel | 36% | 387.65 | 484 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 28% | 14.49 | 8 / 29 |
eye | 0% | 0 | 0 / 0 | 18% | 7.42 | 14 / 80 |
peripheral blood | 8% | 78.48 | 71 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0031642 | Biological process | negative regulation of myelination |
GO_0042552 | Biological process | myelination |
GO_0001783 | Biological process | B cell apoptotic process |
GO_0050852 | Biological process | T cell receptor signaling pathway |
GO_0032693 | Biological process | negative regulation of interleukin-10 production |
GO_0006959 | Biological process | humoral immune response |
GO_0007413 | Biological process | axonal fasciculation |
GO_0002250 | Biological process | adaptive immune response |
GO_0071356 | Biological process | cellular response to tumor necrosis factor |
GO_0051402 | Biological process | neuron apoptotic process |
GO_0032696 | Biological process | negative regulation of interleukin-13 production |
GO_0042130 | Biological process | negative regulation of T cell proliferation |
GO_0048713 | Biological process | regulation of oligodendrocyte differentiation |
GO_0006915 | Biological process | apoptotic process |
GO_0032714 | Biological process | negative regulation of interleukin-5 production |
GO_0097252 | Biological process | oligodendrocyte apoptotic process |
GO_0030889 | Biological process | negative regulation of B cell proliferation |
GO_0005886 | Cellular component | plasma membrane |
GO_0030424 | Cellular component | axon |
GO_0005515 | Molecular function | protein binding |
Gene name | TNFRSF21 |
Protein name | BM-018 (TNFRSF21 protein) Tumor necrosis factor receptor superfamily member 21 (Death receptor 6) (CD antigen CD358) Alternative protein TNFRSF21 |
Synonyms | DR6 UNQ437/PRO868 |
Description | FUNCTION: Promotes apoptosis, possibly via a pathway that involves the activation of NF-kappa-B. Can also promote apoptosis mediated by BAX and by the release of cytochrome c from the mitochondria into the cytoplasm. Plays a role in neuronal apoptosis, including apoptosis in response to amyloid peptides derived from APP, and is required for both normal cell body death and axonal pruning. Trophic-factor deprivation triggers the cleavage of surface APP by beta-secretase to release sAPP-beta which is further cleaved to release an N-terminal fragment of APP (N-APP). N-APP binds TNFRSF21; this triggers caspase activation and degeneration of both neuronal cell bodies (via caspase-3) and axons (via caspase-6). Negatively regulates oligodendrocyte survival, maturation and myelination. Plays a role in signaling cascades triggered by stimulation of T-cell receptors, in the adaptive immune response and in the regulation of T-cell differentiation and proliferation. Negatively regulates T-cell responses and the release of cytokines such as IL4, IL5, IL10, IL13 and IFNG by Th2 cells. Negatively regulates the production of IgG, IgM and IgM in response to antigens. May inhibit the activation of JNK in response to T-cell stimulation. Also acts as a regulator of pyroptosis: recruits CASP8 in response to reactive oxygen species (ROS) and subsequent oxidation, leading to activation of GSDMC . . |
Accessions | O75509 Q9NZD9 ENST00000296861.2 L8E6S5 |